New York State Psychiatric Institute psychedelic research trials
Data as of 31 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.
New York State Psychiatric Institute is listed with 13 registered studies counted here, in New York, United States. By compound: 4 psilocybin and 9 ketamine. By registry status: 1 recruiting, 1 not yet recruiting, 1 active, not recruiting, 7 completed and 3 terminated. By phase: 2 phase 1, 5 phase 2, 3 phase 3 and 3 phase 4. Reported start years run from 2009 (earliest) to 2026 (latest).
Institution name, city and country are copied from the research site linked to each registry record. A study counts once per institution, and a study tagged with more than one compound is counted under each compound.
Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.
At a glance
- 13 registered studies are counted on this page.
By compound
| Compound hub | Studies |
|---|---|
| Psilocybin | 4 |
| Ketamine | 9 |
By registry status
| Status | Studies | Share |
|---|---|---|
| Recruiting | 1 | 8% |
| Not yet recruiting | 1 | 8% |
| Active, not recruiting | 1 | 8% |
| Completed | 7 | 54% |
| Terminated | 3 | 23% |
By phase
| Phase | Studies | Share |
|---|---|---|
| Phase 1 | 2 | 15% |
| Phase 2 | 5 | 38% |
| Phase 3 | 3 | 23% |
| Phase 4 | 3 | 23% |
Registered studies
All counted studies, newest start first. Dates may be estimated, including future dates; a listed date does not confirm that a study started. The order is not a ranking and says nothing about quality. Titles are quoted from the registry. Each ID links to its own ClinicalTrials.gov record, which has the eligibility criteria and contacts.
| Title as registered | Registry ID | Status | Phase | Registry dates | Compound |
|---|---|---|---|---|---|
| Understanding the Role of the Kappa Opioid Receptor in Ketamine's Attenuation of Suicidal Thoughts | NCT07139106 | Not yet recruiting | Phase 4 | Source start: 2026-10-01 (estimated) Saved start 2026-02-01 differs from reported 2026-10-01; the saved day is not established by this observation. Source date detailsStart: 2026-10-01 (precision: day; source type: ESTIMATED; estimated) Primary completion: 2028-10-01 (precision: day; source type: ESTIMATED; estimated) Study completion: 2028-10-01 (precision: day; source type: ESTIMATED; estimated) Observation retrieved: 2026-10-31T20:06:18.160Z; registry revision: 2026-08-03 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. | Ketamine |
| A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder | NCT06793397 | Recruiting | Phase 3 | Source start: 2025-12-10 (actual)Source date detailsStart: 2025-12-10 (precision: day; source type: ACTUAL; actual) Primary completion: 2027-06-07 (precision: day; source type: ESTIMATED; estimated) Study completion: 2027-08-09 (precision: day; source type: ESTIMATED; estimated) Observation retrieved: 2026-10-31T20:06:17.780Z; registry revision: 2026-10-30 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. | Psilocybin |
| Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD | NCT05711940 | Active, not recruiting | Phase 3 | Source start: 2023-02-14 (actual)Source date detailsStart: 2023-02-14 (precision: day; source type: ACTUAL; actual) Primary completion: 2025-11-13 (precision: day; source type: ACTUAL; actual) Study completion: 2026-12 (precision: month; source type: ESTIMATED; estimated) Observation retrieved: 2026-10-31T20:06:16.639Z; registry revision: 2026-08-10 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. | Psilocybin |
| Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD | NCT05624268 | Completed | Phase 3 | Source start: 2023-01-24 (actual) Saved start 2023-01-19 differs from reported 2023-01-24; the saved day is not established by this observation. Source date detailsStart: 2023-01-24 (precision: day; source type: ACTUAL; actual) Primary completion: 2025-05-28 (precision: day; source type: ACTUAL; actual) Study completion: 2026-04-15 (precision: day; source type: ACTUAL; actual) Observation retrieved: 2026-10-31T20:06:16.599Z; registry revision: 2026-08-10 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. | Psilocybin |
| The Role of HNKs in the Antidepressant Effect of Ketamine | NCT03977675 | Terminated | Phase 1 | Source start: 2019-05-15 (actual)Source date detailsStart: 2019-05-15 (precision: day; source type: ACTUAL; actual) Primary completion: 2020-07-02 (precision: day; source type: ACTUAL; actual) Study completion: 2020-07-02 (precision: day; source type: ACTUAL; actual) Observation retrieved: 2026-10-31T20:06:15.077Z; registry revision: 2021-01-22 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. | Ketamine |
| The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression | NCT03775200 | Completed | Phase 2 | Source start: 2019-03-01 (actual)Source date detailsStart: 2019-03-01 (precision: day; source type: ACTUAL; actual) Primary completion: 2021-07-30 (precision: day; source type: ACTUAL; actual) Study completion: 2021-09-27 (precision: day; source type: ACTUAL; actual) Observation retrieved: 2026-10-31T20:06:14.687Z; registry revision: 2023-04-24 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. | Psilocybin |
| Randomized Controlled Trial of Intranasal Ketamine vs. Intranasal Midazolam in Individuals With OCD | NCT02206776 | Terminated | Phase 2 | Source start: 2014-09 (type unknown) Saved start 2014-09-01 differs from reported 2014-09; the saved day is not established by this observation. Source date detailsStart: 2014-09 (precision: month; source type: not reported; unknown) Primary completion: 2015-05 (precision: month; source type: ACTUAL; actual) Study completion: 2015-05 (precision: month; source type: ACTUAL; actual) Observation retrieved: 2026-10-31T20:06:13.506Z; registry revision: 2017-05-03 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. | Ketamine |
| Biomarker Assessment of Glutamatergic Target Engagement | NCT02134951 | Completed | Phase 4 | Source start: 2014-05 (type unknown) Saved start 2014-05-01 differs from reported 2014-05; the saved day is not established by this observation. Source date detailsStart: 2014-05 (precision: month; source type: not reported; unknown) Primary completion: 2015-10 (precision: month; source type: ACTUAL; actual) Study completion: 2015-11 (precision: month; source type: ACTUAL; actual) Observation retrieved: 2026-10-31T20:06:13.506Z; registry revision: 2018-08-17 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. | Ketamine |
| NMDA Antagonists in Bipolar Depression | NCT01833897 | Completed | Phase 4 | Source start: 2013-03 (type unknown) Saved start 2013-03-01 differs from reported 2013-03; the saved day is not established by this observation. Source date detailsStart: 2013-03 (precision: month; source type: not reported; unknown) Primary completion: 2014-07 (precision: month; source type: ACTUAL; actual) Study completion: 2016-03 (precision: month; source type: ACTUAL; actual) Observation retrieved: 2026-10-31T20:06:13.146Z; registry revision: 2016-06-01 (precision: day; source type: ESTIMATED; estimated). Source observations do not verify a different saved scalar or establish that an event occurred. | Ketamine |
| The Effect of Brief Potent Glutamatergic Modulation on Cocaine Dependence | NCT01535937 | Terminated | Phase 1 | Source start: 2012-02 (actual) Saved start 2012-02-01 differs from reported 2012-02; the saved day is not established by this observation. Source date detailsStart: 2012-02 (precision: month; source type: ACTUAL; actual) Primary completion: 2017-01 (precision: month; source type: ACTUAL; actual) Study completion: 2017-04 (precision: month; source type: ACTUAL; actual) Observation retrieved: 2026-10-31T20:06:13.115Z; registry revision: 2019-05-01 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. | Ketamine |
| Ketamine in the Treatment of Depression | NCT01558063 | Completed | Phase 2 | Source start: 2012-02 (type unknown) Saved start 2012-02-01 differs from reported 2012-02; the saved day is not established by this observation. Source date detailsStart: 2012-02 (precision: month; source type: not reported; unknown) Primary completion: 2015-05 (precision: month; source type: ACTUAL; actual) Study completion: 2019-10 (precision: month; source type: ACTUAL; actual) Observation retrieved: 2026-10-31T20:06:13.115Z; registry revision: 2019-12-10 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. | Ketamine |
| Pilot Study of Ketamine in Adults With Obsessive-Compulsive Disorder (OCD) | NCT01100255 | Completed | Phase 2 | Source start: 2010-04 (type unknown) Saved start 2010-04-01 differs from reported 2010-04; the saved day is not established by this observation. Source date detailsStart: 2010-04 (precision: month; source type: not reported; unknown) Primary completion: 2015-12 (precision: month; source type: ACTUAL; actual) Study completion: 2015-12 (precision: month; source type: ACTUAL; actual) Observation retrieved: 2026-10-31T20:06:12.737Z; registry revision: 2017-02-20 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. | Ketamine |
| Memantine Augmentation in Treatment-Resistant Adults With Obsessive-Compulsive Disorder | NCT00956085 | Completed | Phase 2 | Source start: 2009-08 (type unknown) Saved start 2009-08-01 differs from reported 2009-08; the saved day is not established by this observation. Source date detailsStart: 2009-08 (precision: month; source type: not reported; unknown) Primary completion: 2015-12 (precision: month; source type: ACTUAL; actual) Study completion: 2015-12 (precision: month; source type: ACTUAL; actual) Observation retrieved: 2026-10-31T20:06:12.748Z; registry revision: 2017-06-21 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. | Ketamine |
About this data
Compound tags come from automated matching of the registry search term and have not been checked record by record. Counts are of registered studies, not of people, results or approvals. A registry listing is not evidence of safety, benefit or results.
Substance hubs for these compounds
Country hub: United States